BGM0504 + metformin

BGM0504 + metformin is a combination therapy under clinical development for the treatment of type 2 diabetes mellitus and obesity. BGM0504 is an investigational, once-weekly subcutaneously administered dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR), developed by BrightGene Bio-Medical Technology. Metformin is a widely used oral biguanide that reduces hepatic glucose production and improves insulin sensitivity. The combination is being evaluated in clinical trials, including a Phase III trial in China comparing BGM0504 to semaglutide as an add-on therapy to metformin in patients with type 2 diabetes whose blood glucose is inadequately controlled by metformin alone. Additionally, a Phase I drug-drug interaction study has evaluated the effects of BGM0504 on the pharmacokinetics of metformin in overweight or obese participants.